Detecting doping with a bacterial enzyme
With the 2016 Olympic Games drawing to a close, it’s fair to say that doping in sport is being more closely scrutinised than ever. It is therefore particularly timely that Australian National University (ANU) researchers are developing a new way to detect performance-enhancing drugs at major sporting events.
The team are engineering a bacterial enzyme that could help detect many banned drugs over longer time frames compared with current anti-doping tests. The enzyme interacts with a drug in a urine or blood sample, and works by cleaving off part of the drug to make it easier to analyse.
“It’s an enzyme from bacteria that is found in all sorts of environments, which we’ve purified and studied,” said team leader Dr Malcolm McLeod. The researchers revealed their initial findings on the enzyme’s potential anti-doping applications in a 2015 paper published in the journal Drug Testing and Analysis.
Since this publication, Dr McLeod and his colleagues have received funding from the World Anti-Doping Agency to change the enzyme’s structure. Not only will this enable it to detect more banned substances, it could also enable labs to detect doping for a longer period after an athlete takes a banned drug.
“We’re working with a biotechnology company in Chile to evaluate the improved enzymes, and they have sent them to three analytical labs around the world,” said Dr McLeod. One of these laboratories conducts anti-doping tests for sporting events.
“We hope this enzyme will quickly become a powerful tool used by labs in the fight against doping in sport,” concluded Dr McLeod.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...